JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: BMS-833923 (also known as XL139; BMS833923; XL-139; BMS 833923) is a novel, potent, selective, and orally bioavailable inhibitor of SMO (Smoothened) with potential antineoplastic activity. It inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM. BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway. BMS-833923 robustly inhibits HH pathway activity with along duration of action after a single oral dose in medulloblastoma and pancreatic carcinoma xenograft models.
References: Cancer Invest. 2013 Aug; 31(7):480-9; Prostate. 2013 Dec; 73(16):1810-23.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!